> Nanobiotix secured a €40 million ($47 million) loan from the European Investment Bank. The French biotech will use the money to develop NBTXR3 in head and neck cancers. Statement
> BioLineRx added an arm to its phase 2a BL-8040-Keytruda combination trial. The arm will assess the effect on second-line pancreatic cancer patients of adding chemotherapy to the regimen. Release
> Takeda completed its takeover of TiGenix. Statement
> Mologen named Ignacio Faus as CEO. Release
> Kymab committed to moving its OX40L antagonist into a phase 2 atopic dermatitis trial after getting a look at data from an early-stage clinical study. Statement